Skip to main content

Table 1 Characteristics of included trials

From: Vitamin C for preventing atrial fibrillation in high risk patients: a systematic review and meta-analysis

Trial (ref.) Country Setting No. of Participants Mean age (yr) Proportion males
van Wagoner 2003 [27] USA CABG 346 63 NA
Donovan 2012 [30] USA CABG or valvular surgery 304 64 76%
Sadeghpour 2015 [31] Iran CABG or valvular surgery 290 56 66%
Bjordahl 2012 [18] USA CABG 185 63 67%
Papoulidis 2011 [21] Greece CABG 170 73 71%
Sarzaeem 2014 [26] Iran CABG 170 59 69%
Samadikhah 2014 [25] Iran CABG 120 61 68%
Antonic 2016 [23] Slovenia CABG 105 64 78%
Dehghani 2014 [19] Iran CABG 100 61 74%
Eslami 2007 [20] Iran CABG 100 60 67%
Korantzopoulos 2005 [32] Greece Cardioversion 44 68 59%
Rebrova 2012 [24] Russia CABG 40 59 100%
Healy 2010 [29] USA CABG or valvular surgery 30 NA NA
Colby 2011 [28] USA CABG or valvular surgery 24 65 79%
Polymeropoulos 2015 [22] Greece CABG 22 70 59%
  1. The trials are listed by the number of patients. The two largest trials [27, 30], both carried out at the USA, have not been published because of their negative findings. For the US trials, the weighted mean age was 63.4 years and for the non-US trials, it was 61.8 years. For the US trials, the overall proportion of males was 73%, and for the non-US trials, it was 70%
  2. CABG Coronary artery bypass grafting, NA Not available